Restoration of Brain Acid Soluble Protein 1 Inhibits Proliferation and Migration of Thyroid Cancer Cells

Background:Brain acid soluble protein 1 (BASP1) is identified as a novel potential tumor suppressor in several cancers. However, its role in thyroid cancer has not been investigated yet. In the present study, the antitumor activities of BASP1 against the growth and migration of thyroid cancer cells were evaluated. Methods:BASP1 expression in thyroid cancer tissues and normal tissues were examined by immunohistochemical staining and the association between its expression and prognosis was analyzed. pcDNA-BASP1 carrying full length of BASP1 cDNA was constructed to restore the expression of BASP1 in thyroid cancer cell lines (BHT-101 and KMH-2). The cell proliferation in vitro and in vivo was evaluated by WST-1 assay and xenograft tumor models, respectively. Cell cycle distribution after transfection was analyzed using flow cytometry. Cell apoptosis after transfection was examined by annexin V/propidium iodide assay. The migration was examined using transwell assay. Results:BASP1 expression was abundant in normal tissues while it is significantly decreased in cancer tissues (P = 0.000). pcDNA-BASP1 restored the expression of BASP1 and significantly inhibited the growth of BHT-101 and KMH-2 cells as well as xenograft tumors in nude mice (P = 0.000). pcDNA-BASP1 induced G1 arrest and apoptosis in BHT-101 and KMH-2 cells. In addition, pcDNA-BASP1 significantly inhibited the cell migration. Conclusions:Downregulation of BASP1 expression may play a role in the tumorigenesis of thyroid cancer. Restoration of BASP1 expression exerted extensive antitumor activities against growth and migration of thyroid cancer cells, which suggested that BASP1 gene might act as a potential therapeutic agent for the treatment of thyroid cancer.

[1]  Yoshihiko Hamamoto,et al.  Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. , 2008, International journal of oncology.

[2]  Y. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer , 2003, Cancer science.

[3]  Matthias Mann,et al.  BASP1 Is a Transcriptional Cosuppressor for the Wilms' Tumor Suppressor Protein WT1 , 2004, Molecular and Cellular Biology.

[4]  M. Beuran,et al.  The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[5]  M. Prasad,et al.  Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis. , 2014, JAMA surgery.

[6]  Xiaoping Zhang,et al.  MicroRNA role in thyroid cancer pathogenesis. , 2013, Frontiers in bioscience.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  Jianping Zhang,et al.  MicroRNA‐191, by promoting the EMT and increasing CSC‐like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells , 2015, Molecular carcinogenesis.

[9]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[10]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[11]  Li-shan Wang,et al.  High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. , 2012, Oncology reports.

[12]  R. DeLellis.  Pathology and genetics of thyroid carcinoma , 2006, Journal of surgical oncology.

[13]  F. Marano,et al.  Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. , 2013, Thyroid : official journal of the American Thyroid Association.

[14]  Zheming Lu,et al.  Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma , 2013, Journal of the Chinese Medical Association : JCMA.

[15]  H. Sugiyama.  WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. , 2010, Japanese journal of clinical oncology.

[16]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[17]  Jingting Jiang,et al.  Wilms’ tumor 1 enhances Cisplatin‐resistance of advanced NSCLC , 2014, FEBS letters.

[18]  Axel Hauschild,et al.  Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays , 2015, Melanoma research.

[19]  C. Muñoz-Pinedo,et al.  Regulation of cancer metabolism by oncogenes and tumor suppressors. , 2014, Methods in enzymology.

[20]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[21]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[22]  P. Vigneri,et al.  The changing epidemiology of thyroid cancer: why is incidence increasing? , 2015, Current opinion in oncology.

[23]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[24]  M. Hartl,et al.  Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1) , 2009, Proceedings of the National Academy of Sciences.

[25]  Wilms’ tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck , 2015, BMC Cancer.

[26]  I. Sugawara,et al.  Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  Hsiang-Yu Lin,et al.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction‐mimetic agent , 2012, The Prostate.

[28]  Stefan G. E. Roberts,et al.  Prohibitin is required for transcriptional repression by the WT1-BASP1 complex , 2013, Oncogene.